21 April 2026

AOTI, INC. (the "Company" or "Group" or "AOTI")

2025 Annual Report and Notice of Annual General Meeting

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces that electronic copies of the Company's Annual Report and Financial Statements for the year ended 31 December 2025, together with the 2026 Notice of Annual General Meeting (the 'Notice'), Form of Instruction and Proxy forms will shortly be available on the Company's website at:

https://aotinc.net/investors/financial-reports-publications-2/

The Annual General Meeting ('AGM') will be held at 10:00am British Summer Time (BST) on Thursday, 21 May 2026 at the offices of Burges Salmon LLP, 6 Great New Street, London, EC4A 3BN, United Kingdom.

Shareholders are encouraged to vote on the resolutions to be put to the AGM by proxy whether or not they intend to attend. Voting by proxy prior to the AGM does not affect shareholders' right to attend the AGM and vote in person should they so wish. Holders of Depositary Interests will be sent a Form of Instruction for voting their shares and all other shareholders will be sent the Notice and Form of Proxy; with all items posted on or around 22 April 2026.

Full details of the operation and arrangements for the AGM are set out in the Notice.

ENDS

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent. reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO₂^® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net